Frdric Perros

List of Publications by Citations

112 papers	7,789 citations	44 h-index	87 g-index
146 ext. papers	9,142 ext. citations	8.5 avg, IF	5.53 L-index

#	Paper	IF	Citations
112	House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. *Nature Medicine*, **2009**, 15, 410-6	50.5	835
111	Inflammation in pulmonary arterial hypertension. *European Respiratory Journal*, **2003**, 22, 358-63	13.6	473
110	Pulmonary arterial hypertension in patients treated by dasatinib. *Circulation*, **2012**, 125, 2128-37	16.7	448
109	Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 81-8	10.2	336
108	Endothelial-to-mesenchymal transition in pulmonary hypertension. *Circulation*, **2015**, 131, 1006-18	16.7	320
107	Diagnosis and Classification of 17 Diseases from 1404 Subjects via Pattern Analysis of Exhaled Molecules. *ACS Nano*, **2017**, 11, 112-125	16.7	279
106	Inflammation in pulmonary arterial hypertension. *Chest*, **2012**, 141, 210-221	5.3	279
105	Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 780-9	10.2	244
104	Tertiary lymphoid organs in infection and autoimmunity. *Trends in Immunology*, **2012**, 33, 297-305	14.4	241
103	Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. *Human Pathology*, **2007**, 38, 893-902	3.7	238
102	Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 311-21	10.2	194
101	Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 176, 1041-7	10.2	173
100	Pulmonary arterial hypertension. *Orphanet Journal of Rare Diseases*, **2013**, 8, 97	4.2	168
99	C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 184, 116-23	10.2	147
98	Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. *European Respiratory Journal*, **2007**, 29, 462-8	13.6	137
97	Pulmonary veno-occlusive disease. *European Respiratory Journal*, **2016**, 47, 1518-34	13.6	134
96	Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. *European Respiratory Journal*, **2007**, 29, 937-43	13.6	124

95	Chemotherapy-induced pulmonary hypertension: role of alkylating agents. *American Journal of Pathology*, **2015**, 185, 356-71	5.8	116
94	Blockade of CCR4 in a humanized model of asthma reveals a critical role for DC-derived CCL17 and CCL22 in attracting Th2 cells and inducing airway inflammation. *Allergy: European Journal of Allergy and Clinical Immunology*, **2009**, 64, 995-1002	9.3	112
93	Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay. *Circulation*, **2014**, 129, 1332-40	16.7	110
92	Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. *Journal of the American College of Cardiology*, **2015**, 65, 668-80	15.1	101
91	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. *Circulation*, **2016**, 133, 1371-85	16.7	98
90	Evidence for the involvement of type I interferon in pulmonary arterial hypertension. *Circulation Research*, **2014**, 114, 677-88	15.7	97
89	Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 583-595	10.2	95
88	miR-223 reverses experimental pulmonary arterial hypertension. *American Journal of Physiology - Cell Physiology*, **2015**, 309, C363-72	5.4	91
87	Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension. *Vascular Pharmacology*, **2008**, 49, 113-8	5.9	90
86	Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. *European Respiratory Journal*, **2012**, 40, 895-904	13.6	84
85	Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. *Circulation*, **2015**, 132, 834-47	16.7	80
84	Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. *European Respiratory Journal*, **2011**, 37, 1392-9	13.6	78
83	Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. *European Respiratory Journal*, **2011**, 37, 813-22	13.6	75
82	The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. *Clinical Reviews in Allergy and Immunology*, **2013**, 44, 31-8	12.3	73
81	A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 666-76	10.2	68
80	Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. *Respiratory Research*, **2011**, 12, 119	7.3	64
79	Nuclear factor EB is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension. *PLoS ONE*, **2013**, 8, e75415	3.7	62
78	Role for Runt-related Transcription Factor 2 in Proliferative and Calcified Vascular Lesions in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 1273-1285	10.2	61

77	TLR4 signalling in pulmonary stromal cells is critical for inflammation and immunity in the airways. *Respiratory Research*, **2011**, 12, 125	7.3	60
76	Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. *European Respiratory Journal*, **2015**, 46, 1721-31	13.6	55
75	T-helper 17 cell polarization in pulmonary arterial hypertension. *Chest*, **2015**, 147, 1610-1620	5.3	52
74	Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. *Circulation*, **2019**, 139, 932-948	16.7	50
73	Potassium channels in pulmonary arterial hypertension. *European Respiratory Journal*, **2015**, 46, 1167-77	13.6	49
72	Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. *Biochemical and Biophysical Research Communications*, **2014**, 451, 8-14	3.4	47
71	NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension. *Circulation*, **2018**, 137, 2371-2389	16.7	46
70	Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?. *Seminars in Respiratory and Critical Care Medicine*, **2013**, 34, 714-24	3.9	45
69	Characterization of -Mutated Rat, a Novel Model of Pulmonary Hypertension. *Circulation Research*, **2019**, 125, 678-695	15.7	42
68	Cytotoxic cells and granulysin in pulmonary arterial hypertension and pulmonary veno-occlusive disease. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 189-96	10.2	42
67	Use of Blockers in Pulmonary Hypertension. *Circulation: Heart Failure*, **2017**, 10,	7.6	41
66	Inflammation in pulmonary hypertension: what we know and what we could logically and safely target first. *Drug Discovery Today*, **2014**, 19, 1251-6	8.8	39
65	A proof of concept for the detection and classification of pulmonary arterial hypertension through breath analysis with a sensor array. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 756-9	10.2	37
64	Sirtuin 1 regulates pulmonary artery smooth muscle cell proliferation: role in pulmonary arterial hypertension. *Journal of Hypertension*, **2018**, 36, 1164-1177	1.9	36
63	Ca handling remodeling and STIM1L/Orai1/TRPC1/TRPC4 upregulation in monocrotaline-induced right ventricular hypertrophy. *Journal of Molecular and Cellular Cardiology*, **2018**, 118, 208-224	5.8	34
62	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. *Respiratory Research*, **2014**, 15, 65	7.3	34
61	Bromodomain and extra-terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: Implications for pulmonary arterial hypertension. *Respirology*, **2017**, 22, 157-164	3.6	33
60	Current insights on the pathogenesis of pulmonary arterial hypertension. *Seminars in Respiratory and Critical Care Medicine*, **2005**, 26, 355-64	3.9	33

59	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. *Cardiovascular Research*, **2018**, 114, 880-893	9.9	31
58	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. *Journal of Heart and Lung Transplantation*, **2018**, 37, 647-655	5.8	31
57	Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series). *Pulmonary Circulation*, **2016**, 6, 448-464	2.7	31
56	Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. *Oncotarget*, **2017**, 8, 52995-53016	3.3	30
55	Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 148-157	10.2	29
54	Pulmonary microvascular lesions regress in reperfused chronic thromboembolic pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2015**, 34, 457-67	5.8	26
53	Gut-Lung Connection in Pulmonary Arterial Hypertension. *American Journal of Respiratory Cell and Molecular Biology*, **2017**, 56, 402-405	5.7	25
52	MicroRNA networks in pulmonary arterial hypertension: share mechanisms with cancer?. *Current Opinion in Oncology*, **2016**, 28, 72-82	4.2	25
51	Familial pulmonary arterial hypertension by heterozygous loss of function. *European Respiratory Journal*, **2020**, 55,	13.6	23
50	Imatinib inhibits bone marrow-derived c-kit+ cell mobilisation in hypoxic pulmonary hypertension. *European Respiratory Journal*, **2010**, 36, 1209-11	13.6	23
49	Respiratory effects of trichloroethylene. *Respiratory Medicine*, **2018**, 134, 47-53	4.6	22
48	Systematic analysis of blood cell transcriptome in end-stage chronic respiratory diseases. *PLoS ONE* , **2014**, 9, e109291	3.7	20
47	Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: Toward contractile versus synthetic phenotypes. *Proteomics*, **2016**, 16, 2637-2649	4.8	18
46	Pulmonary hypertension associated with neurofibromatosis type 1. *European Respiratory Review*, **2018**, 27,	9.8	18
45	Dexamethasone induces apoptosis in pulmonary arterial smooth muscle cells. *Respiratory Research*, **2015**, 16, 114	7.3	16
44	Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. *American Journal of Pathology*, **2019**, 189, 1159-1175	5.8	14
43	BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators. *Pflugers Archiv European Journal of Physiology*, **2016**, 468, 1969-1983	4.6	12
42	Early Development of Right Ventricular Ischemic Lesions in a Novel Large Animal Model of Acute Right Heart Failure in Chronic Thromboembolic Pulmonary Hypertension. *Journal of Cardiac Failure*, **2017**, 23, 876-886	3.3	12

41	The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	11
40	Phenotype and outcome of pulmonary arterial hypertension patients carrying a mutation. *European Respiratory Journal*, **2020**, 55,	13.6	11
39	The integrated stress response system in cardiovascular disease. *Drug Discovery Today*, **2018**, 23, 920-928	8.8	11
38	Smooth Muscle Phenotype in Idiopathic Pulmonary Hypertension: Hyper-Proliferative but not Cancerous. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	11
37	T-type Ca channels elicit pro-proliferative and anti-apoptotic responses through impaired PP2A/Akt1 signaling in PASMCs from patients with pulmonary arterial hypertension. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2017**, 1864, 1631-1641	4.9	11
36	Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. *American Journal of Respiratory Cell and Molecular Biology*, **2020**, 63, 118-131	5.7	11
35	In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression. *Respiratory Research*, **2020**, 21, 186	7.3	10
34	Vitamin D deficiency downregulates TASK-1 channels and induces pulmonary vascular dysfunction. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2020**, 319, L627-L640	5.8	10
33	Pulmonary capillary haemangiomatosis: a distinct entity?. *European Respiratory Review*, **2020**, 29,	9.8	9
32	The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats. *PLoS ONE*, **2013**, 8, e77073	3.7	9
31	Understanding the role of CD4+CD25(high) (so-called regulatory) T cells in idiopathic pulmonary arterial hypertension. *Respiration*, **2008**, 75, 253-6	3.7	7
30	Iron Deficiency in Pulmonary Arterial Hypertension: A Deep Dive into the Mechanisms. *Cells*, **2021**, 10,	7.9	7
29	Oral 15-Hydroxyeicosatetraenoic Acid Induces Pulmonary Hypertension in Mice by Triggering T Cell-Dependent Endothelial Cell Apoptosis. *Hypertension*, **2020**, 76, 985-996	8.5	6
28	Circulating fibrocytes and pulmonary arterial hypertension. *European Respiratory Journal*, **2012**, 39, 210-2	13.6	5
27	Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension. *European Respiratory Journal*, **2021**, 58,	13.6	5
26	Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. *Chest*, **2021**, 159, 1197-1207	5.3	5
25	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 843-852	10.2	4
24	A simple method to assess in vivo proliferation in lung vasculature with EdU: the case of MMC-induced PVOD in rat. *Analytical Cellular Pathology*, **2015**, 2015, 326385	3.4	4

23	Identity crisis in pulmonary arterial hypertension. *Pulmonary Circulation*, **2018**, 8, 2045893217746054	2.7	4
22	Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model". *Circulation*, **2016**, 133, e592-3	16.7	4
21	Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. *Cardiovascular Research*, **2021**, 117, 2474-2488	9.9	4
20	-blockers in pulmonary arterial hypertension: generation might matter. *European Respiratory Journal*, **2016**, 47, 682-4	13.6	3
19	Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. *International Journal of Clinical Pharmacy*, **2018**, 40, 790-794	2.3	3
18	Central Role of Dendritic Cells in Pulmonary Arterial Hypertension in Human and Mice. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
17	CXCL13 in tertiary lymphoid tissues: sites of production are different from sites of functional localization. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 369-70	10.2	2
16	A study of magnesium deficiency in human and experimental pulmonary hypertension. *Magnesium Research*, **2012**, 25, 21-7	1.7	2
15	S154 Is there a role for IL-33 in the pathogenesis of pulmonary arterial hypertension?. *Thorax*, **2010**, 65, A70-A70	7.3	2
14	Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats. *European Respiratory Journal*, **2009**, 34, 731-9	13.6	2
13	Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary veno-occlusive disease. *Pulmonary Circulation*, **2020**, 10, 2045894020907884	2.7	1
12	Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension **2020**, 63-70		1
11	Inflammation in Pulmonary Arterial Hypertension **2012**, 213-229		1
10	Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension.. *European Respiratory Review*, **2021**, 30,	9.8	1
9	BET Bromodomain Inhibitors and Pulmonary Arterial Hypertension: Take Care of the Heart. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1187-1188	10.2	0
8	Association between Leflunomide and Pulmonary Hypertension. *Annals of the American Thoracic Society*, **2021**, 18, 1306-1315	4.7	0
7	Response by Mendes-Ferreira et al to Letter Regarding Article, "Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension". *Circulation*, **2019**, 140, e288-e289	16.7	
6	Response. *Chest*, **2015**, 148, e132-e133	5.3	

5	S6 The profiles of JMJD3, UTX and H3K27me3 expression in pulmonary vasculature in rat MCT model of PAH and human iPAH: implications for pulmonary arterial hypertension. *Thorax*, **2015**, 70, A7-A8	7.3
4	S142 The role of H3K27 methylation in vascular endothelial cell proliferation and function: implications for pulmonary arterial hypertension. *Thorax*, **2013**, 68, A73.1-A73	7.3
3	S152 Dexamethasone reverses established monocrotaline-induced pulmonary hypertension in rats and increases pulmonary BMPR2 expression. *Thorax*, **2010**, 65, A68-A69	7.3
2	P29 Endothelial cell NF-kB activation is increased in human idiopathic PAH. *Thorax*, **2010**, 65, A88-A89	7.3
1	Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2. *Communications Biology*, **2021**, 4, 1002	6.7